9 Myths About Antidepressants as a First-Line Menopause Treatment That Leave Women Undertreated
There's a particular kind of gaslighting that happens when you're handed a prescription for depression you didn't know you had, for a hormonal transition no one mentioned. So many women describe relief just from learning that what they're feeling has a physiological name — and fury that it took so long for someone to tell them.
Learn more about Rose →Myth: If a woman feels depressed, she probably has depression — not a hormone problem
Estrogen plays a direct role in regulating serotonin, dopamine, and norepinephrine — the same neurotransmitters targeted by antidepressants. When estrogen fluctuates and drops during perimenopause, mood instability, tearfulness, and low motivation can follow as a direct neurochemical consequence rather than a psychiatric condition. Treating the hormonal driver is physiologically distinct from treating a serotonin-deficit disorder, and conflating the two leads to undertreatment.
Myth: Antidepressants are equally effective as HRT for hormonal mood symptoms
Randomized controlled trials comparing estrogen therapy to SSRIs for perimenopausal mood symptoms consistently show estrogen performs at least as well — and in some studies, better — particularly for women who are not clinically depressed. A pivotal NIMH-funded trial found that transdermal estradiol significantly reduced depressive symptoms in perimenopausal women, while placebo-controlled SSRI trials in this population show more modest effects. The two treatments work on fundamentally different mechanisms, and the hormonal one addresses the root cause.
Myth: Prescribing an antidepressant is a safe, low-risk first step
SSRIs and SNRIs carry their own side-effect profiles — including sexual dysfunction, weight changes, emotional blunting, and discontinuation syndrome — that are rarely foregrounded during a brief consultation. For a woman whose mood symptoms are driven by estrogen fluctuation rather than a serotonin deficit, she is absorbing these risks without addressing the actual problem. Starting with a treatment that doesn't match the mechanism is not neutral; it delays the right intervention and introduces new burdens.
Myth: Women in perimenopause with mood symptoms are simply more vulnerable to depression
Perimenopause is a recognized period of heightened neurological sensitivity to hormonal change, but that is not the same as an intrinsic psychiatric vulnerability. Research shows the mood symptoms most common in perimenopause — irritability, emotional reactivity, low mood — track closely with estradiol variability rather than with classic major depressive disorder patterns. Labeling hormonal sensitivity as psychiatric vulnerability pathologizes a normal biological transition.
Myth: If sleep improves on an antidepressant, the treatment is working
Some antidepressants, particularly mirtazapine and low-dose tricyclics, have sedating properties that can improve sleep architecture independently of their antidepressant mechanism. But in perimenopause, sleep disruption is frequently driven by vasomotor symptoms — night sweats and hot flushes that fragment sleep throughout the night. Improved sleep on a sedating antidepressant may mask the hormonal driver entirely rather than resolving it, leaving women on medication they may not need for a problem that has a more targeted solution.
Myth: Anxiety in perimenopause is a separate condition from the hormonal transition
New-onset anxiety or a significant worsening of pre-existing anxiety in perimenopause has strong mechanistic links to estrogen's role in regulating the amygdala and the HPA (stress response) axis. When estrogen drops, the brain's threat-detection system becomes less regulated, which is experienced as heightened anxiety, hypervigilance, and panic — often with no clear psychological trigger. Treating this with an anxiolytic or antidepressant without assessing hormonal status means treating the alarm without addressing what set it off.
Myth: Women who respond to antidepressants must have had a true psychiatric condition
Antidepressants — particularly SNRIs like venlafaxine — do have a modest effect on hot flushes and some mood symptoms in menopause, which can make them appear to be the right treatment. However, a partial response to a medication does not retroactively confirm the diagnosis that medication is typically prescribed for. The fact that venlafaxine reduces flush frequency by around 50% in some studies confirms it has off-label utility, not that the underlying problem was a serotonin or norepinephrine deficit.
Myth: HRT is too risky to consider before trying an antidepressant
The 2002 WHI study created widespread fear about hormone therapy that has since been substantially revised through reanalysis and decades of subsequent research — yet that fear continues to shape prescribing patterns. For healthy women under 60 or within ten years of menopause onset, current evidence from the British Menopause Society, the Menopause Society, and NICE places the absolute risks of appropriately prescribed HRT as low and the benefits as meaningful. The risk calculation that makes antidepressants feel 'safer' is based on outdated data, not current evidence.
Myth: Raising the hormonal angle with a doctor is the patient's job, not the system's
Medical guidelines from NICE, the British Menopause Society, and the Menopause Society explicitly state that clinicians should consider hormonal causes when perimenopausal women present with mood symptoms — meaning the onus to investigate is on the practitioner, not the patient. The fact that women routinely have to advocate for themselves, often after one or more antidepressant prescriptions, reflects a training and awareness gap rather than a reasonable clinical process. Women deserve a system that asks the hormonal question first, not one that requires them to fight for it.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.